Steris stock (IE00BFY8C754): Q4 earnings miss, analyst targets cut

Steris plc reported fourth-quarter fiscal 2026 adjusted earnings of $2.83 per share, up 3.3% year over year, but the result fell short of analyst expectations, according to Zacks as of May 12, 2026. The stock dipped in aftermarket trading following the announcement. Revenue for the quarter reached $1.6 billion, exceeding the anticipated $1.59 billion, providing a partial offset to the earnings miss.

The mixed results triggered analyst downgrades on May 13, 2026. KeyBanc adjusted its price target on Steris to $269 from $291 while maintaining an Overweight rating, according to MT Newswires as of May 13, 2026. Jefferies also cut its price target to $225 from $253, maintaining a Hold rating, according to MT Newswires as of May 13, 2026. The stock traded at $210.85 USD on May 13, 2026, up 4.46% on the day.

As of: May 13, 2026

By the editorial team – specialized in equity coverage.

Steris: core business model

Steris is one of the world's leading providers of infection control solutions and procedural services. The company operates across three primary segments: infection control solutions, which includes cleaning and sterilization chemicals, accessories for gastrointestinal procedures, washers, sterilizers, and operating room equipment such as surgical tables and lighting systems; applied sterilization solutions, encompassing contract development of sterilization modalities and laboratory testing services; and consumables and maintenance equipment dedicated to pharmaceutical manufacturers. This diversified portfolio positions Steris as a critical infrastructure provider for healthcare systems and pharmaceutical operations globally.

Main revenue and product drivers for Steris

Infection control solutions represent the largest revenue segment at 71.1% of net sales, driven by ongoing demand for sterilization and cleaning products in hospitals and surgical centers. Applied sterilization solutions contribute 19% of revenue through contract development and laboratory testing services for over 50 sterilization and laboratory facilities worldwide. The consumables and maintenance equipment segment, representing 9.9% of revenue, serves pharmaceutical manufacturers with specialized products. For US investors, Steris's exposure to the American healthcare system—particularly acute care hospitals and the pharmaceutical manufacturing sector—makes it a play on healthcare infrastructure spending and infection prevention trends.

Conclusion

Steris reported mixed fourth-quarter fiscal 2026 results, with earnings missing consensus expectations despite revenue beating forecasts. The earnings miss and subsequent analyst downgrades from KeyBanc and Jefferies reflect investor concerns about the company's near-term performance trajectory. For US investors tracking healthcare infrastructure and infection control exposure, the stock's reaction to these results and the divergence between analyst ratings—with KeyBanc maintaining Overweight while Jefferies holds—underscores the importance of monitoring upcoming guidance and operational execution in the sterilization and infection control markets.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.